CTNNB1 and Miyoshi myopathy: Among the anti-MM agents tested, only carfilzomib (data not shown) had a cell death profile similar to HDACi, with OPM2 and U266 being resistant, whereas other agents including inhibitors of signaling pathways (JAK-STAT (janus kinase/signal transducers and activators of transcription)),22 of beta-catenin, notch signaling (unpublished results) and of Class III HDAC (Sirtuins)23 had quite distinctive effects on HMCL dissimilar to those induced by HDACi.